Xenon downgraded at Deutsche Bank on trial pause (XENE:NASDAQ)
· seekingalpha.com
Xenon Pharmaceuticals (XENE) stock drops as the firm pauses enrollement in late-stage depression trials for lead asset. Deutsche Bank downgrades. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...